International pharmacopsychiatry最新文献

Nomifensine--clinical and experimental investigation. 诺非芬——临床和实验研究。

International pharmacopsychiatry Pub Date : 1982-09-01 DOI: 10.1159/isbn.978-3-318-06224-3

W. Pöldinger, K. Taeuber

引用次数: 0

Nomifensine and maprotiline in endogenous depression: comparative efficacy and side effects. 诺非芬与马普替林治疗内源性抑郁症的疗效及副作用比较。

International pharmacopsychiatry Pub Date : 1982-01-01 DOI: 10.1159/000468603

A Levin

引用次数: 7

Antidepressant effect of Ro 11-1163, a new MAO inhibitor.

International pharmacopsychiatry Pub Date : 1982-01-01 DOI: 10.1159/000468556

C N Stefanis, B H Alevizos, G N Papadimitriou

引用次数: 30

On the relationship between free plasma and saliva amitriptyline and nortriptyline. 游离血浆和唾液中阿米替林和去甲替林的关系。

International pharmacopsychiatry Pub Date : 1982-01-01 DOI: 10.1159/000468569

P Baumann, D Tinguely, L Koeb, J Schöpf, P K Le

引用次数: 18

Prediction of clinical efficacy of zopiclone by utilizing two psychophysiological tools in healthy volunteers. 利用两种心理生理工具预测佐匹克隆在健康志愿者中的临床疗效。

International pharmacopsychiatry Pub Date : 1982-01-01

K Inanaga, M Tanaka, Y Mizuki

引用次数: 0

Effects of zopiclone as compared to flurazepam on sleep in women over 40 years of age. 佐匹克隆与氟拉西泮对40岁以上女性睡眠的影响

International pharmacopsychiatry Pub Date : 1982-01-01

O P Quadens, G Hoffman, G Buytaert

{"title":"Effects of zopiclone as compared to flurazepam on sleep in women over 40 years of age.","authors":"O P Quadens, G Hoffman, G Buytaert","doi":"","DOIUrl":"","url":null,"abstract":"Zopiclone is a new nonbenzodiazepine hypnotic, the recommended dose of which is 7.5 mg. It was compared to flurazepam 30 mg in a sleep laboratory study. 12 women aged 40-60 years, with subjective sleep disorders for at least 2 months, were treated for 13 nights with each drug in a crossover double-blind design. Each active drug period was preceded by 5 days of placebo washout and followed by 35 days of withdrawal (no treatment). A baseline period of 4 nights (without treatment) was obtained before the study itself. The subjects slept in the sleep laboratory during the baseline period, during the last 3 nights on placebo, during the last 3 nights on active drug, and from the 11th to the 13th night after active drug discontinuation. Polygraphic recordings were obtained during each of these nights. The criteria of Kales and Rechtschaffen were used to score the tracings. Both drugs were shown to be effective when compared to placebo. Comparisons between the two periods with active treatment did not show significant differences for sleep onset latency, total sleep time, sleep efficiency index, stage 0, percent REM, number of REM periods, and REM latency. There was a trend towards an increase with zopiclone of the number of awakenings, percent of stage 3, percent of deep sleep, and an increase with flurazepam of the percent of light sleep. A significant difference was only found for percent of stage 2 (increased with flurazepam).","PeriodicalId":75943,"journal":{"name":"International pharmacopsychiatry","volume":"17 Suppl 2 ","pages":"146-55"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18200978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetics and metabolism of zopiclone. 佐匹克隆的药代动力学和代谢。

International pharmacopsychiatry Pub Date : 1982-01-01

J Gaillot, D Heusse, G W Hougton, J Marc Aurele, J F Dreyfus

{"title":"Pharmacokinetics and metabolism of zopiclone.","authors":"J Gaillot, D Heusse, G W Hougton, J Marc Aurele, J F Dreyfus","doi":"","DOIUrl":"","url":null,"abstract":"Pharmacokinetics and metabolism of a new hypnotic, zopiclone (ZD), were studied under the following conditions: (1) rats and dogs were given oral doses of the molecule, 14C-labeled either on the side chain or on the pyrrolopyrazine nucleus; (2) rats, rabbits and dogs were given increasing oral doses of the cold compound; (3) human subjects in various physiopathological situations - young and elderly healthy volunteers, patients with liver or renal impairments, nursing mothers - were given single or repeated doses, p.o. or i.v. (range 3.5-15 mg). ZD is rapidly and efficiently absorbed: its oral bioavailability was greater than 75% in all species except rats, where a first-pass effect of about 65% was recorded. Plasma protein binding is about 45%. The radioactive material rapidly diffuses from the vascular compartment, with a marked affinity for the brain. Plasma kinetics of ZD are generally well described by a two-compartment open model; in man, terminal half-life is 4-5 h; total body clearance is large (300 ml/mn), renal clearance very low (10 ml/min). The relationship between doses and concentrations, doses and urinary excretion of unchanged compound and major metabolites was linear in all species, except rabbits. The major metabolic routes involve decarboxylation affecting more than 50% of dose (rats and dogs), N-demethylation and N-oxidation - more than 30% as N-desmethyl and N-oxide derivatives in urine (humans). Due to intensive metabolism, only 7-10% of the dose is recovered in urine and feces as unchanged compounds (all species). In nursing mothers, milk and plasma kinetics of ZD are similar with a milk/plasma ratio around 0.80. In human volunteers, plasma half-life of ZD increases with age, while patients with liver or renal impairments show little or no modification of pharmacokinetic parameters.","PeriodicalId":75943,"journal":{"name":"International pharmacopsychiatry","volume":"17 Suppl 2 ","pages":"76-91"},"PeriodicalIF":0.0,"publicationDate":"1982-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18204207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypnotic effects of a benzodiazepine derivative: a clinical observation. 苯二氮卓衍生物的催眠作用:临床观察。

International pharmacopsychiatry Pub Date : 1982-01-01 DOI: 10.1159/000468557

Y Kudo

引用次数: 7

(Des-Tyr)gamma-endorphin for schizophrenia. A critical review. (Des-Tyr) -内啡肽治疗精神分裂症。批判性的评论。

International pharmacopsychiatry Pub Date : 1982-01-01 DOI: 10.1159/000468570

R Manchanda, S R Hirsch

引用次数: 1

Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. 吡拉西坦对抗精神病药物所致锥体外系不良反应的影响。

International pharmacopsychiatry Pub Date : 1982-01-01

J Kabes, J Sikora, J Pisvejc, L Hanzlicek, V Skondia

引用次数: 0